Literature DB >> 21030071

Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study.

Nabihah Sachedina1, Liam J Donaldson.   

Abstract

BACKGROUND: Young people (aged 0-18 years) have been disproportionately affected by pandemic influenza A H1N1 infection. We aimed to analyse paediatric mortality to inform clinical and public health policies for future influenza seasons and pandemics.
METHODS: All paediatric deaths related to pandemic influenza A H1N1 infection from June 26, 2009, to March 22, 2010 in England were identified through daily reporting systems and cross-checking of records and were validated by confirmation of influenza infection by laboratory results or death certificates. Clinicians responsible for each individual child provided detailed information about past medical history, presentation, and clinical course of the acute illness. Case estimates of influenza A H1N1 were obtained from the Health Protection Agency. The primary outcome measures were population mortality rates and case-fatality rates.
FINDINGS: 70 paediatric deaths related to pandemic influenza A H1N1 were reported. Childhood mortality rate was 6 per million population. The rate was highest for children aged less than 1 year. Mortality rates were higher for Bangladeshi children (47 deaths per million population [95% CI 17-103]) and Pakistani children (36 deaths per million population [18-64]) than for white British children (4 deaths per million [3-6]). 15 (21%) children who died were previously healthy; 45 (64%) had severe pre-existing disorders. The highest age-standardised mortality rate for a pre-existing disorder was for chronic neurological disease (1536 per million population). 19 (27%) deaths occurred before inpatient admission. Children in this subgroup were significantly more likely to have been healthy or had only mild pre-existing disorders than those who died after admission (p=0·0109). Overall, 45 (64%) children had received oseltamivir: seven within 48 h of symptom onset.
INTERPRETATION: Vaccination priority should be for children at increased risk of severe illness or death from influenza. This group might include those with specified pre-existing disorders and those in some ethnic minority groups. Early pre-hospital supportive and therapeutic care is also important. FUNDING: Department of Health, UK.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21030071     DOI: 10.1016/S0140-6736(10)61195-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  54 in total

1.  Socio-economic disparities in mortality due to pandemic influenza in England.

Authors:  Paul D Rutter; Oliver T Mytton; Matthew Mak; Liam J Donaldson
Journal:  Int J Public Health       Date:  2012-08       Impact factor: 3.380

2.  Children with special health care needs and preparedness: experiences from seasonal influenza and the 2009 H1N1 influenza pandemic.

Authors:  Georgina Peacock; Cynthia Moore; Timothy Uyeki
Journal:  Disaster Med Public Health Prep       Date:  2012-06       Impact factor: 1.385

3.  Critically ill children during the 2009-2010 influenza pandemic in the United States.

Authors:  Adrienne G Randolph; Frances Vaughn; Ryan Sullivan; Lewis Rubinson; B Taylor Thompson; Grace Yoon; Elizabeth Smoot; Todd W Rice; Laura L Loftis; Mark Helfaer; Allan Doctor; Matthew Paden; Heidi Flori; Christopher Babbitt; Ana Lia Graciano; Rainer Gedeit; Ronald C Sanders; John S Giuliano; Jerry Zimmerman; Timothy M Uyeki
Journal:  Pediatrics       Date:  2011-11-07       Impact factor: 7.124

Review 4.  Impact of H1N1 on socially disadvantaged populations: summary of a systematic review.

Authors:  Andrea C Tricco; Erin Lillie; Charlene Soobiah; Laure Perrier; Sharon E Straus
Journal:  Influenza Other Respir Viruses       Date:  2013-09       Impact factor: 4.380

5.  Trend of morbidity related to pandemic Influenza A (H1N1) infection in a tertiary care teaching institution in south India.

Authors:  B Adhisivam; Sitanshu Sekhar Kar; S Sujatha; T K Dutta
Journal:  Indian J Pediatr       Date:  2011-06-25       Impact factor: 1.967

6.  Neurologic complications of influenza A(H1N1)pdm09: surveillance in 6 pediatric hospitals.

Authors:  Gulam Khandaker; Yvonne Zurynski; Jim Buttery; Helen Marshall; Peter C Richmond; Russell C Dale; Jenny Royle; Michael Gold; Tom Snelling; Bruce Whitehead; Cheryl Jones; Leon Heron; Mary McCaskill; Kristine Macartney; Elizabeth J Elliott; Robert Booy
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

7.  Extension of influenza immunization program to children in England - Future plans.

Authors:  Pauline MacDonald
Journal:  Hum Vaccin Immunother       Date:  2016-10-02       Impact factor: 3.452

8.  2009 H1N1: risk factors for hospitalization in a matched case-control study.

Authors:  Cristian Launes; Juan-José García-García; Aina Martínez-Planas; Fernando Moraga; Itziar Astigarraga; Javier Arístegui; Javier Korta; Concepción Salado; José M Quintana; Núria Soldevila; Angela Domínguez
Journal:  Eur J Pediatr       Date:  2012-03-21       Impact factor: 3.183

9.  Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.

Authors:  Markus Knuf; Geert Leroux-Roels; Hans Rümke; Luis Rivera; Paola Pedotti; Ashwani Kumar Arora; Maria Lattanzi; Dorothee Kieninger; Giovanni Della Cioppa
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 10.  Case fatality risk of influenza A (H1N1pdm09): a systematic review.

Authors:  Jessica Y Wong; Heath Kelly; Dennis K M Ip; Joseph T Wu; Gabriel M Leung; Benjamin J Cowling
Journal:  Epidemiology       Date:  2013-11       Impact factor: 4.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.